ONC201 demonstrated (GI50 1 - 8 µM) dose - and time - dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B - cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T - cell lymphoma (CTCL), Hodgkin's lymphoma (
nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples.
The researchers found five different sub-types of HL among the patients studied: 247 cases of
the nodular sclerosis (NS) type, in which the tumour nodules are large; 105 of mixed cellularity, where a mixture of different types of inflammatory cells are involved; 58 lymphocyte rich, the sub-type with the best outcome; 68 «others»; and 143 «not otherwise specified» (NOS).